O-demethyltramadol (O-desmethyltramadol)

one of the major metabolites of tramadol; structure given in first source; RN given refers to parent compound

Also Known As:

O-desmethyltramadol; O-demethyl tramadol; O-demethyltramadol hydrochloride; tramadol M1 metabolite

Networked: 14 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Methylamines: 15
    - Dimethylamines
      - Tramadol: 2983
        O-demethyltramadol: 14
- Alcohols: 595
  - Fatty Alcohols: 172
    - Hexanols: 17
      - Cyclohexanols: 41
        Tramadol: 2983
        O-demethyltramadol: 14
Lipids: 114793
- Fatty Alcohols: 172
  - Hexanols: 17
    - Cyclohexanols: 41
      - Tramadol: 2983
        O-demethyltramadol: 14

Experts

1.	Ahmadimanesh, Mahnaz: 2 articles (06/2020 - 01/2020)
2.	Ghazi-Khansari, Mahmoud: 2 articles (06/2020 - 01/2020)
3.	Naeini, Mehri Bemani: 2 articles (06/2020 - 01/2020)
4.	Rouini, Mohammad-Reza: 2 articles (06/2020 - 01/2020)
5.	Shadnia, Shahin: 2 articles (06/2020 - 01/2020)
6.	Debeljak, Zeljko: 1 article (01/2021)
7.	Kristek, Gordana: 1 article (01/2021)
8.	Kvolik, Slavica: 1 article (01/2021)
9.	Mandic, Dario: 1 article (01/2021)
10.	Marczi, Saska: 1 article (01/2021)

Related Diseases

1.	Postoperative Pain 03/01/2010 - "Thus, the authors aimed to examine the potential role of serotonergic descending bulbospinal pathways and spinal 5-HT7 receptors compared with that of the 5-HT2A and 5-HT3 receptors in the antinociceptive and antihyperalgesic effects of tramadol and its major active metabolite O-desmethyltramadol (M1) on phasic and postoperative pain models. " 01/01/2021 - "The aim of this study was 1) to measure concentrations of tramadol, O-demethyltramadol (ODT), and N-demethyltramadol (NDT) in the surgical patients admitted to the intensive care unit (ICU) within the first 24 postoperative hours after intravenous application of tramadol, and 2) to examine the effect of systemic inflammation on tramadol metabolism and postoperative pain. "
2.	Overweight 08/01/2019 - "No significant differences were found in the pharmacokinetics of tramadol and O-desmethyltramadol, indicating that the opioid can be administered to overweight, obese and diabetic patients without dosage adjustment." 08/01/2019 - "The aim of the study was to assess the influence of overweight, obesity and type 2 diabetes mellitus on tramadol and O-desmethyltramadol pharmacokinetics. "
3.	Obesity 08/01/2019 - "The aim of the study was to assess the influence of overweight, obesity and type 2 diabetes mellitus on tramadol and O-desmethyltramadol pharmacokinetics. "
4.	Neuralgia (Stump Neuralgia) 10/01/2008 - "The present study was designed to investigate the rewarding effects induced by tramadol and its active metabolite O-desmethyltramadol (M1) under a neuropathic pain-like state. "
5.	Inflammation (Inflammations) 01/01/2021 - "The aim of this study was 1) to measure concentrations of tramadol, O-demethyltramadol (ODT), and N-demethyltramadol (NDT) in the surgical patients admitted to the intensive care unit (ICU) within the first 24 postoperative hours after intravenous application of tramadol, and 2) to examine the effect of systemic inflammation on tramadol metabolism and postoperative pain. "

Related Drugs and Biologics

1.	Tramadol (K315)
2.	N-demethyltramadol
3.	Biomarkers (Surrogate Marker)
4.	Serotonin (5 Hydroxytryptamine)
5.	Opioid Receptors (Opioid Receptor)
6.	Krypton
7.	Opioid Analgesics (Opioids)
8.	Analgesics (Analgesic Drugs)
9.	Celecoxib (Celebrex)

Related Therapies and Procedures

1.	Analgesia